Inicio・Lista de Acciones・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Abierto

SectorSanidad

2.99 -1.32

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

3.07

Métricas clave
By Trading Economics
Ingresos	-9.4M -118M
Ventas	-29M 6.5M
BPA	-0.22
Margen de beneficios	-1,815.575
Empleados	600
EBITDA	-13M -102M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+139.61% upside

Dividendos
By Acuity
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-334M 1.5B
Apertura anterior	4.31
Cierre anterior	2.99

Noticias sobre sentimiento de mercado

By Acuity

50%

145 / 340 Clasificación en Healthcare

Recursion Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 jul 2026, 23:51 UTC

Recursion Pharmaceuticals Inc's shares are lower in after-market hours, settling down from Tuesday's close without any specific news to explain the movement.

20 jul 2026, 19:46 UTC

Correlated Moves

Recursion Pharmaceuticals is declining, continuing a trend from previous sessions, amid broader declines in the ARK Genomic Revolution ETF and Russell 2000 Index.

Comparación entre iguales

Cambio de precio

Recursion Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

139.61% repunte

Estimación a 12 Meses

Media 7.38 USD 139.61%

Máximo 10 USD

Mínimo 5.5 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Recursion Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Recursion Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

145 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.